Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-19T22:36:26.738Z Has data issue: false hasContentIssue false
  • English
  • Français

An open letter to the Executive Editor of the British National Formulary

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Ann Barker

In the preface to the BNF you state that “comments and constructive criticism will be welcome”. I should like to ask a question. I should like to know how members of the Committee reach a decision on what dose should be considered the upper limit of medication, and in particular psychotropic medication, commonly known as “the BNF maximum”.

Type
Briefings
Information
Psychiatric Bulletin , Volume 17 , Issue 9 , September 1993 , pp. 557
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists 1993
Submit a response

eLetters

No eLetters have been published for this article.